19 Recruiting Follicular Lymphoma Phase 2 Clinical Trials
Active phase 2 studies for follicular lymphoma enrolling across the USA. Verify eligibility and contact site coordinators.
All Follicular Lymphoma studiesPhase 2 Studies for Follicular Lymphoma
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
📍 Weill Cornell Medicine/NewYork-Presbyterian Hospital — New York, New York
View Study & Checklist ➔Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
View Study & Checklist ➔A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
📍 City of Hope National Medical Center — Duarte, California
View Study & Checklist ➔Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
📍 Northwestern University — Chicago, Illinois
View Study & Checklist ➔Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
📍 Advocate Medical Group - Park Ridge, Luther Lane - Oncology — Park Ridge, Illinois
View Study & Checklist ➔A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
📍 MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
📍 Yale Cancer Center — New Haven, Connecticut
View Study & Checklist ➔Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
📍 Florida Cancer Specialists and Research Institute — Fort Myers, Florida
View Study & Checklist ➔Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
📍 Masonic Cancer Center — Minneapolis, Minnesota
View Study & Checklist ➔A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
📍 Duke Cancer Center Clinic 1B/C Onc/Heme ( Site 1307) — Durham, North Carolina
View Study & Checklist ➔A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
📍 Dana Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
📍 Georgetown University (Data Collection Only) — Washington D.C., District of Columbia
View Study & Checklist ➔Odronextamab in Low Tumor Volume Advanced FL
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
View Study & Checklist ➔Epco, Zanu, Ritux for R/R FL or MZL
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔Epcoritamab and Rituximab for First-line Follicular Lymphoma
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
View Study & Checklist ➔